secwatch.observer — SEC 8-K summary
======================================

Issuer:     Chemomab Therapeutics Ltd. (CMMB)
CIK:        0001534248
Form:       8-K
Filed at:   2022-06-08T23:59:59+00:00
Accession:  0001178913-22-002314
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Chemomab reports 2022 Annual Meeting vote results; all proposals pass
---------------------------------------------------------------------

- Proposal 1: re-elect Dr. Nissim Darvish as Class I director received 84,055,680 FOR, 591,060 AGAINST.
- Proposal 2: approve amendment to compensation of Dr. Adi Mor (CSO) passed with 83,840,260 FOR.
- Proposal 4: reappoint Somekh Chaikin (KPMG) as auditor approved with 84,152,640 FOR.
- Proposal 3 (equity grants to directors) was withdrawn prior to the meeting.
- Total shares represented: 84,756,220 ordinary (37.16% of outstanding).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534248/000117891322002314/0001178913-22-002314-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534248/000117891322002314/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001178913-22-002314

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer